The rapid expansion of illicit peptide use in Australia: Emerging risks and regulatory pressure points

The rapid rise of illicit and unapproved peptide use in Australia is creating a complex and evolving challenge across public health, regulation, and enforcement. Once limited to niche or underground markets, peptides are now widely promoted for performance enhancement, weight management, anti-ageing, and recovery, driven by a digitally enabled, consumer-focused ecosystem. 

This shift has been accelerated by the convergence of online advertising, influencer-led demand, and increasingly sophisticated supply chains. These hybrid models blur the distinction between legitimate compounding practices, prescription medicines, and unlawful therapeutic goods, making it more difficult for regulators and investigators to clearly identify compliant versus illicit activity. 

The scale and trajectory of this growth carry significant implications for Australia’s regulatory environment. While existing regulatory frameworks under the Therapeutic Goods Act 1989 provide a strong legal foundation, enforcement pressure is increasing due to: 

• Rapid expansion of online supply channels 

• Cross-border importation complexity 

• Misleading advertising through social media and telehealth-style platforms 

• Growth in self-directed injectable use without clinical oversight 

Context and market evolution 

The current peptide landscape in Australia reflects a structural shift in how unapproved therapeutic goods are accessed and consumed. 

Historically, misuse of performance and image enhancing drugs was concentrated in anabolic steroid markets. However, peptide-based compounds are now increasingly positioned as “lifestyle therapeutics” rather than traditional performance drugs. 

The demand environment is being shaped by digital channels that normalise and commercialise self-administration of injectable substances outside of medical supervision. 

The market is increasingly consumer-led rather than prescriber-led, with clinical governance often occurring ad hoc or not at all. 

Safety alert issued amid explosion of illegal peptide use The medicines regulator issues a health alert about the risks of using unregulated peptides amid a surge in the use of potentially unsafe injectables. Read full article.

Emerging supply chain and distribution dynamics  

The illicit peptide market is increasingly characterised by hybridised distribution models, including: 

• Online clinic ecosystems - Platforms presenting as telehealth services facilitate access to peptide prescriptions or supply pathways with minimal clinical engagement. 

• Offshore manufacturing and direct shipping - Products are frequently sourced internationally and imported directly by consumers or intermediaries, often labelled as “research use only”. 

• Social media-enabled demand generation - Influencer marketing and user-generated content normalise injectable peptide use and position it as routine wellness practice. 

• Compounding ambiguity - The boundary between legitimate compounding pharmacy activity and unapproved mass supply is increasingly difficult to delineate in online environments. 

Traditional approval mechanisms are increasingly insufficient to manage dynamic, platform-based distribution models.  

‘Tons of money’: How China supplies untested peptides to the West In nondescript office blocks across China, salespeople are pitching injectable drugs to overseas customers, fuelling a fast-growing black market in peptides. Read full article.

Investigation capability gap and case complexity  

The expansion of illicit peptide supply has fundamentally altered the investigative environment faced by regulators. 

Investigations are no longer discrete, transaction-based inquiries. Instead, they are multi-layered digital and physical reconstructions of distributed supply ecosystems involving overlapping actors, jurisdictions, and platforms. 

A central challenge is that evidentiary material is inherently fragmented. Relevant information may be distributed across: 

• social media advertising ecosystems 

• encrypted or ephemeral messaging platforms

• evolving e-commerce storefronts 

• telehealth-style prescribing interfaces 

• importation and customs datasets 

• domestic compounding and distribution pathways 

Investigators need to operate across multiple domains simultaneously while maintaining evidentiary integrity and procedural consistency. Traditional case management approaches may not optimised for fast-moving, digitally native supply networks where evidence is dynamic, distributed, and often transient. 

Case growth pressures 

The expansion of illicit peptide supply would be he impacting the volume and in some cases the complexity of regulatory investigations. This growth may be compounded, driven by the continuous emergence of new online suppliers, advertising channels, and cross-border import pathways. 

In many cases the investigative workload could shift from a manageable number of discrete cases to a continuous intake environment, without corresponding changes in investigative infrastructure, this can lead bottlenecks in: 

• initial case assessment and prioritisation 

• evidence collation across fragmented digital sources 

• mapping of conduct to legislative offence elements 

• preparation of coherent briefs of evidence 

These pressures increase the likelihood of inconsistent case progression timelines and can create variability in investigative outcomes depending on team workload and resource availability at any given time. 

The role of AI-enabled Investigation tools  

To address these constraints, regulatory environments need to adopt AI-enabled investigative tools designed to improve both speed and consistency in case processing. 

In this context, The Comtrac AI Investigator Suite embeds secure, purpose-built AI across key stages of the investigative workflow, combining AI-assisted evidence mapping with a frontline mobile app. 

AI-assisted evidence mapping  

Comtrac’s AI-assisted evidence mapping embeds secure, purpose-built AI directly into your investigation matrix. The AI analyses case data and exhibits relevant to an offence, extracting key evidence to support findings while identifying hidden connections and patterns that may otherwise be overlooked. Investigators can simply drag and drop exhibits into the matrix, where AI automatically surfaces evidence aligned to specific allegations. 

Frontline mobile app 

The Comtrac Frontline mobile app, available on iOS and Android, streamlines field evidence collection by enabling investigators to capture field notes, witness statements, interviews, photographs, and other critical materials directly into Comtrac. AI services enable real-time analysis and summarisation of in-field interviews, allowing for the rapid generation of witness statements for review and signature in the field. 

AI tools such as these allow investigators to focus more directly on analytical decision-making and enforcement strategy, rather than administrative paperwork and the manual assembly of case materials. 

Conclusion and regulatory considerations 

The illicit peptide market in Australia represents a rapidly evolving regulatory challenge characterised by digital distribution, consumer-driven demand, and fragmented cross-border supply chains. 

While the legislative framework remains strong, enforcement effectiveness is increasingly constrained by: 

• distributed digital evidence environments 

• rapid reconstitution of supply networks 

• fragmented and unstructured investigative data sources 

• increasing complexity of multi-jurisdictional coordination 

• growing case volumes placing sustained pressure on investigative throughput 

In response to these pressures, regulatory agencies can increasingly moving toward the adoption of AI-assisted investigative tools and integrated investigation management systems to support scalability, consistency, and timeliness in enforcement activity. These capabilities are becoming essential in managing the pace and complexity of regulatory areas such as this.

Sustained regulatory effectiveness in this environment is likely to depend on the development and adoption of integrated investigative infrastructure, AI-assisted evidence mapping and summarisation capabilities, standardised evidence-to-offence methodologies aligned to legislative frameworks, and improved cross-agency data coordination.